General Information of Drug (ID: DM9YI2C)

Drug Name
ErepoXen Drug Info
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM9YI2C

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin Receptor (EPOR) TTAUX24 EPOR_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erythropoietin Receptor (EPOR) DTT EPOR 5.166 4.594 4.469 4.763
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erythropoietin Receptor (EPOR) DTT EPOR 7.04E-01 0.11 0.27
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033828)
2 Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.